DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

EGFR-positive lung cancer is a type of non-small cell lung cancer (NSCLC). It can cause symptoms such as breathing problems and hoarseness. Therapy that targets the mutation, such as EGFR ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

So, this is how osimertinib will be used in the NHS. People with EGFR mutation-positive NSCLC whose tumours have been surgically removed (complete resection) have the option of then having ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...